The facilitating role of chemotherapy in the palliative phase of cancer: Qualitative interviews with advanced cancer patients

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Buiting, Hilde M ^a,b   Terpstra, Wim ^c   Dalhuisen, Floriske ^a   Gunnink Boonstra, Nicolette ^c   Sonke, Gabe S ^a,d   Hartogh, Govert Den ^b  

^a Department of Registry and Research ^*  (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^d ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; AGED; ARTICLE; AWARENESS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOCTOR PATIENT RELATION; FEMALE; HUMAN; MALE; MEDICAL DECISION MAKING; MEDICAL INFORMATION; NEEDS ASSESSMENT; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT ATTITUDE; PATIENT DECISION MAKING; PHYSICIAN ATTITUDE; PROFESSIONAL COMPETENCE; PROFESSIONAL KNOWLEDGE; QUALITATIVE ANALYSIS; TERMINAL CARE;

AGED; AGED, 80 AND OVER; ATTITUDE TO DEATH; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; PALLIATIVE CARE; PATIENT ACCEPTANCE OF HEALTH CARE; PROFESSIONAL-PATIENT RELATIONS;

EID: 84892389584     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077959     Document Type: Article

References (42)

1. Nappa U, Lindqvist O, Rasmussen BH, Axelsson B (2011) Palliative chemotherapy during the last month of life. Ann Oncol 22 (11): 2375-80.
2. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, et al (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20(11): 1842-7.
3. Oostendorp LJ, Stalmeier PF, Donders AR, van der Graaf WT, Ottevanger PB (2011) Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review. Lancet Oncol 12(11): 1053-61.
4. Oncoline. Available: www.oncoline.nl. Accessed 3 September 2013.
5. Schuette W, Tesch H, Buttner H, Krause T, Soldatenkova V, et al (2012) Second-line treatment of stage III/IV non-small-cell lung cancer (NSCLC) with pemetrexed in routine clinical practice: evaluation of performance status and health-related quality of life. BMC Cancer 13; 12: 14.
6. Harrington SE, Smith TJ (2008) The role of chemotherapy at the end of life: "when is enough, enough?". JAMA 299(22): 2667-78.
7. Cardoso F, Di LA, Lohrisch C, Bernard C, Ferreira F, et al (2002) Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?. Ann Oncol 13(2): 197-207.
8. Pasman HR, Brandt HE, Deliens L, Francke AL (2009) Quality indicators for palliative care: a systematic review. J Pain Symptom Manage 38(1): 145-56.
9. Ho TH, Barbera L, Saskin R, Lu H, Neville BA, et al (2011) Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada. J Clin Oncol 29(12): 1587-91.
10. Tang ST, Wu SC, Hung YN, Chen JS, Huang EW, et al (2009) Determinants of aggressive end-of-life care for Taiwanese cancer decedents, 2001 to 2006. J Clin Oncol 27(27): 4613-8.
11. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC et al (2008) Aggressiveness of cancer care near the end of life: is it a quality-of-care issue?. J Clin Oncol 26(23): 3860-6.
12. [In Dutch] Handreiking: Tijdig spreken over het levenseinde. Available: http://knmg.artsennet.nl/Publicaties/KNMGpublicatie/Handreiking-Tijdig-spreken- over-het-levenseinde-2013.htm. Accessed 3 September 2013.
13. Buiting HM, Rurup ML, Wijsbek H, van Zuylen L, den Hartogh G (2011) Understanding provision of chemotherapy to patients with end stage cancer: qualitative interview study. BMJ 342: d1933.
14. Mack JW, Cronin A, Taback N, Huskamp HA, Keating NL, et al (2012) End-of-life care discussions among patients with advanced cancer: a cohort study. Ann Intern Med 156(3): 204-10.
15. Mack JW, Weeks JC, Wright AA, Block SD, Prigerson HG (2010) End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences. J Clin Oncol 28(7): 1203-8.
16. van Laarhoven HW, Schilderman J, Verhagen CA, Vissers KC, Prins J (2011) Perspectives on death and an afterlife in relation to quality of life, depression, and hopelessness in cancer patients without evidence of disease and advanced cancer patients. J Pain Symptom Manage 41(6): 1048-59.
17. Greenhalgh T, Taylor R (1997) Papers that go beyond numbers (qualitative research). BMJ 20; 315(7110): 740-3.
18. Ritchie J, Lewis J (2007) Qualitative Research Practice. A guide for social science students and researchers. London: Sage Publications pp 336.
19. Buiting HM, Clayton JM, Butow PN, van Delden JJ, van der Heide A (2011) Artificial nutrition and hydration for patients with advanced dementia: perspectives from medical practitioners in the Netherlands and Australia. Palliat Med 25(1): 83-91.
20. Buiting HM, Willems DL, Pasman HR, Rurup ML, Onwuteaka-Philipsen BD (2011) Palliative treatment alternatives and euthanasia consultations: a qualitative interview study. J Pain Symptom Manage 42(1): 32-43.
21. Pope C, Ziebland S, Mays N (2000) Qualitative research in health care. Analysing qualitative data. BMJ 320(7227): 114-6.
22. Sulmasy DP, Sugarman J (1994) Are withholding and withdrawing therapy always morally equivalent?. J Med Ethics 20(4): 218, 22; discussion 223-4.
23. Barclay S, Maher J (2010) Having the difficult conversations about the end of life. BMJ 341: c4862.
24. Weeks JC, Mack JW, Schrag D (2013) Talking with patients about dying. N Engl J Med 368(5): 480-1.
25. Mack JW, Smith TJ (2012) Reasons why physicians do not have discussions about poor prognosis, why it matters, and what can be improved (2012). J Clin Oncol 30(22): 2715-7.
26. Grant L, Murray SA, Sheikh A (2010) Spiritual dimensions of dying in pluralist societies. BMJ 341: c4859.
27. Balboni T, Balboni M, Paulk ME, Phelps A, Wright A, et al. (2011) Support of cancer patients' spiritual needs and associations with medical care costs at the end of life. Cancer 117(23): 5383-91.
28. Charles C, Gafni A, Whelan T (1997) Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med 44(5): 681-92.
29. Clayton JM, Butow PN, Tattersall MH, Devine RJ, Simpson JM et al. (2007) Randomized controlled trial of a prompt list to help advanced cancer patients and their caregivers to ask questions about prognosis and end-of-life care. J Clin Oncol; Feb 20; 25(6): 715-23.
30. Clayton JM, Butow PN, Waters A, Laidsaar-Powell RC, O'Brien A, et al (2013) Evaluation of a novel individualised communication-skills training intervention to improve doctors' confidence and skills in end-of-life communication. Palliat Med 27(3): 236-43.
31. Stiggelbout AM, Van der Weijden T, De Wit MP, Frosch D, Legare F, et al (2012) Shared decision making: really putting patients at the centre of healthcare. BMJ 344: e256.
32. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, et al (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363(8): 733-42.
33. de Kort S (2009) Aims and reasons. Ethical questions about palliative systemic anticancer therapy. PhD thesis.
34. Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, et al (2012) Patients' expectations about effects of chemotherapy for advanced cancer. New England Journal of Medicine 17(367): 1616.
35. Kiely BE, Soon YY, Tattersall MH, Stockler MR (2011) How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol 29(4): 456-63.
36. Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, et al (2004). Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 22(2): 315-21.
37. Walczak A, Butow PN, Davidson PM, Bellemore FA, Tattersall MH, et al (2013) Patient perspectives regarding communication about prognosis and end-of-life issues: how can it be optimised?. Patient Educ Couns 90(3): 307-14.
38. The AM, Hak T, Koeter G, van Der Wal G (2000) Collusion in doctor-patient communication about imminent death: an ethnographic study. BMJ 321(7273): 1376-81.
39. van Vliet L, Francke A, Tomson S, Plum N, van der Wall E, et al (2013) When cure is no option: how explicit and hopeful can information be given? A qualitative study in breast cancer. Patient Educ Couns 90(3): 315-22.
40. Bensing J, Rimondini M, Visser A (2013) What patients want. Patient Educ Couns 90(3): 287-90.
41. Greer JA, Pirl WF, Jackson VA, Muzikansky A, Lennes IT, et al (2012) Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer. J Clin Oncol 30(4): 394-400.
42. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26(10): 1626-34.